FDA Expands Respiratory Options With First Single-Inhaler Triple Therapy for Asthma Maintenance

The FDA has signaled a major shift in respiratory care by approving budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere; AstraZeneca) for the maintenance treatment of asthma in adults and pediatric patients 12 years and older. This marks the introduction of the first and only triple-combination therapy delivered via a single inhaler for this specific patient population in the US.¹

The Burden of Asthma and Therapeutic Landscape

For pharmacists and clinical specialists, this approval provides a streamlined therapeutic option for patients who remain symptomatic despite standard dual-maintenance treatments.

The clinical necessity for such a therapy is underscored by the current state of asthma management in the US, where approximately 27 million people live with the condition.¹ Despite the widespread availability of dual maintenance therapies, nearly half of patients continue to experience uncontrolled symptoms, characterized by persistent inflammation and bronchoconstriction. These uncontrolled states lead to significant quality-of-life limitations and contribute to nearly 10 million asthma attacks recorded annually in the country. The approval of a single-device triple therapy aims to address these gaps by combining an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) into 1 cohesive delivery system.¹

Data Supporting Approval

The regulatory decision was heavily informed by data from the phase 3 KALOS (NCT04609878) and LOGOS (NCT04609904) trials, which were replicate, randomized, double-blind studies involving approximately 4300 patients. These trials investigated the efficacy and safety of the triple-combination therapy in a broad patient population, including those with and without a history of recent exacerbations.^2,3

The results demonstrated that the triple therapy provided statistically significant and clinically meaningful improvements in lung function when compared with traditional dual-combination ICS/LABA treatments. Furthermore, a key secondary end point revealed a rapid onset of action, with patients experiencing improved lung function within 5 minutes of their first dose.^2,3

Pharmacists should note that no new safety or tolerability signals were identified during these trials, reinforcing the profile of the medication for long-term use.^1-3

Implications for Pharmacy Practice

From a clinical pharmacy perspective, integrating Breztri Aerosphere into asthma protocols offers a significant opportunity to improve medication adherence. Managing asthma often requires patients to juggle multiple inhalers with varying techniques and schedules, which can lead to confusion and suboptimal outcomes. By consolidating 3 distinct mechanisms of action—anti-inflammatory ICS, bronchodilating LABA, and the muscarinic antagonism of a LAMA—into the Aerosphere delivery technology, clinicians can simplify the daily regimen for patients who previously required separate devices to achieve similar triple-therapy coverage. This simplification is particularly relevant for the pediatric population 12 years and older, where adherence challenges are frequently documented.

However, the introduction of this new therapy requires diligent patient counseling and education from the pharmacist. It is critical to communicate that Breztri Aerosphere is strictly a maintenance therapy designed for daily use to prevent symptoms and is not intended to treat acute bronchospasm.¹ Patients must be explicitly instructed that the medication will not replace their rescue inhaler and should never be used to relieve sudden breathing difficulties. This distinction is vital for patient safety, as relying on a maintenance inhaler during an acute attack can lead to dangerous delays in treatment.

Furthermore, pharmacists should be aware of the medication’s broader history and technical specifications. Breztri Aerosphere was initially approved in 2020 for the treatment of chronic obstructive pulmonary disease (COPD) and has since been prescribed to millions of patients globally. Its transition into the asthma market leverages the established Aerosphere pressurized metered-dose inhaler platform, which is already approved in over 90 countries for COPD indications.¹

As this therapy becomes more prevalent in community and hospital pharmacies, the role of the pharmacist will be central to identifying eligible patients who are struggling on dual therapy and ensuring they are trained on the proper inhalation technique to maximize the benefits of this new triple-action approach.

REFERENCES

1. Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older. News release. AstraZeneca. April 28, 2026. Accessed May 8, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/breztri-approved-in-the-us-for-asthma.html

2. Papi A, Wise RA, Jackson DJ, et al; KALOS and LOGOS study investigators. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. Lancet Respir Med. 2026;14(4):350-362. doi:10.1016/S2213-2600(25)00457-6

3. Breztri met primary endpoints in KALOS and LOGOS phase III trials in asthma. News release. AstraZeneca. May 2, 2025. Accessed May 8, 2026. https://www.astrazeneca-us.com/media/press-releases/2025/Breztri-met-primary-endpoints-in-kalos-and-logos-phase-III-trials-in-asthma.html